Dr Philip McCarthy  
Professor of Oncology and Director  
Blood and Marrow Transplant Center  
Department of Medicine  
Roswell Park Cancer Institute de Buffalo, NY

“Treatment approach for the transplant eligible multiple myeloma patient, update and controversies”

**Wednesday, September 9, 2015**

**GLEN Site**  
Room D 02.1312  
8:30 to 9:30

**Learning Objectives**

- What is the role of maintenance post transplant in multiple myeloma?  
- Which agent to use in that setting?  
- Do all patients benefit from this approach?  
- Views on consolidation vs maintenance for both?

**Hôpital Maisonneuve-Rosemont**  
Room 0-80  
Videoconference: https://www.irisreservation.ca  
12:00 to 13:00

- Opinion on one vs two transplants for the transplant eligible myeloma patient  
- Opinion on allogenic transplant in myeloma  
- What should be the decision regarding maintenance for the patient with a CR post transplant?  
- What is the optimal TFI (treatment free interval) for directing the patient towards a second transplant?  
- Is thromboprophylaxis appropriate for maintenance treatment?

**Hôpital Notre-Dame (Pavillon Deschamps)**  
Room I-1176-2  
Live on the Web! www.vpsolution.tv/vspo  
Problems/Questions: 514 813-4510  
17:00 to 18:00

- Is maintenance necessary for all patients or are some benefiting more than others?  
- Discuss different protocols on maintenance with their advantages/disadvantages  
- How do you manage side effects and adjust therapy for maintenance patients?  
- How do you follow up risks on secondary malignancy?

**Thursday, September 10, 2015**

**Jewish General Hospital**  
Room E711  
Videoconference: http://telesanctemcgill.ca/  
12:30 to 13:30

- What is the best approach for the treatment of a multiple myeloma patient eligible for transplant?  
- What are the latest data and recommendation regarding the use of an agent in maintenance after transplant?  
- Which patient is susceptible to benefit from this approach (Which agent? Which patient?)  
- How does the general approach for the transplant eligible patient modified for the high risk cytogenetic patient?  
- What treatment is recommended following maintenance?

**Hôpital du Sacré-Cœur de Montréal**  
Salle G-4115  
Videoconference: https://www.irisreservation.ca  
15:00 to 16:00

- Advantages and disadvantages of maintenance treatment  
- Do all patients benefit from this approach?  
- How do you manage a patient on maintenance therapy?

This event is approved for up to 1 credit by the Office for Continuing Health Professional Education (CHPE). The Office for CHPE, Faculty of Medicine, McGill University is fully accredited by the Committee on Accreditation of Canadian Medical Schools. This event is an Accredited Group Learning Activity as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada. Through a reciprocal agreement between the American Medical Association and the Royal College of Physicians and Surgeons of Canada, the Office for CHPE, Faculty of Medicine, McGill University designates this activity for AMA PRA Category 1 credit up to the maximum number of credit hours noted above. Each physician should claim only credit commensurate with the extent of their participation in the activity. For more information or a complete description of these events, please visit our website at: http://www.medicine.mcgill.ca/oncology/speakers/speakers_visitingspeakers.asp